{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T09:04:29Z","timestamp":1787907869407,"version":"build-2784847793"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":37,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Kirin Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jns.2024.123092","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:04:48Z","timestamp":1718323488000},"page":"123092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Adherence to istradefylline in patients with Parkinson's disease: A group-based trajectory analysis"],"prefix":"10.1016","volume":"462","author":[{"given":"Toshiki","family":"Fukasawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Shinoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Tanaka-Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.123092_bb0005","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-013-0066-7","article-title":"Istradefylline: first global approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.jns.2024.123092_bb0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11302-020-09694-2","article-title":"The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson\u2019s disease","volume":"16","author":"Chen","year":"2020","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.jns.2024.123092_bb0015","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1080\/14656566.2019.1614167","article-title":"Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson\u2019s disease: a single-arm, open-label, prospective, multicenter study","volume":"20","author":"Iijima","year":"2019","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jns.2024.123092_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120078","article-title":"Efficacy and safety of istradefylline in patients with Parkinson\u2019s disease presenting with postural abnormalities: results from a multicenter, prospective, and open-label exploratory study in Japan","volume":"432","author":"Takahashi","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2024.123092_bb0025","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jns.2018.11.005","article-title":"Effect of istradefylline on mood disorders in Parkinson\u2019s disease","volume":"396","author":"Nagayama","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2024.123092_bb0030","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jns.2017.07.045","article-title":"Istradefylline improves daytime sleepiness in patients with Parkinson\u2019s disease: an open-label, 3-month study","volume":"380","author":"Suzuki","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2024.123092_bb0035","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40120-023-00574-6","article-title":"Impact of istradefylline on levodopa dose escalation in Parkinson\u2019s disease: ISTRA ADJUST PD study, a multicenter, open-label, randomized, parallel-group controlled study","volume":"13","author":"Hatano","year":"2024","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.jns.2024.123092_bb0040","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/pds.4334","article-title":"The myths of medication adherence","volume":"26","author":"Gellad","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jns.2024.123092_bb0045","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jns.2024.123092_bb0050","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/MLR.0b013e3182984c1f","article-title":"Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence","volume":"51","author":"Franklin","year":"2013","journal-title":"Med. Care"},{"key":"10.1016\/j.jns.2024.123092_bb0055","series-title":"Group-Based Modeling of Development","author":"Nagin","year":"2005"},{"key":"10.1016\/j.jns.2024.123092_bb0060","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","article-title":"Group-based trajectory modeling in clinical research","volume":"6","author":"Nagin","year":"2010","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/j.jns.2024.123092_bb0065","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/add.15878","article-title":"Changes in predicted opioid overdose risk over time in a state medicaid program: a group-based trajectory modeling analysis","volume":"117","author":"Guo","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.jns.2024.123092_bb0070","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2183\/pjab.98.026","article-title":"Clinical epidemiology and pharmacoepidemiology studies with real-world databases","volume":"98","author":"Yoshida","year":"2022","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.jns.2024.123092_bb0075","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/jth.15799","article-title":"Comparative effectiveness and safety of edoxaban, rivaroxaban, and apixaban in patients with venous thromboembolism: a cohort study","volume":"20","author":"Fukasawa","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jns.2024.123092_bb0080","first-page":"901","article-title":"Incidence of surgical site infection following lateral lumbar interbody fusion compared with posterior\/transforaminal lumbar interbody fusion: a propensity score-weighted study","volume":"48","author":"Masuda","year":"2023","journal-title":"Spine"},{"key":"10.1016\/j.jns.2024.123092_bb0085","author":"Medical and Healthcare Database Utilization Committee"},{"key":"10.1016\/j.jns.2024.123092_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00155","article-title":"An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non\u2013small-cell lung cancer","author":"Stewart","year":"2019","journal-title":"JCO Clin. Cancer Inform."},{"key":"10.1016\/j.jns.2024.123092_bb0095","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/M18-3079","article-title":"Graphical depiction of longitudinal study designs in health care databases","volume":"170","author":"Schneeweiss","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jns.2024.123092_bb0100","first-page":"39","article-title":"Design diagram: a framework for visualizing study designs using real-world data and improving study reproducibility","volume":"28","author":"Fukasawa","year":"2023","journal-title":"Jpn. J. Pharmacoepidemiol."},{"key":"10.1016\/j.jns.2024.123092_bb0105","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/MLR.0000000000001625","article-title":"Comparing continuous and binary group-based trajectory modeling using statin medication adherence data","volume":"59","author":"Hickson","year":"2021","journal-title":"Med. Care"},{"key":"10.1016\/j.jns.2024.123092_bb0110","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/pds.3787","article-title":"Association between trajectories of statin adherence and subsequent cardiovascular events","volume":"24","author":"Franklin","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jns.2024.123092_bb0115","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/cpt.865","article-title":"Group-based trajectory models: assessing adherence to antihypertensive medication in older adults in a community pharmacy setting","volume":"103","author":"Dillon","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jns.2024.123092_bb0120","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.2147\/PPA.S270809","article-title":"Group-based trajectory modeling to identify patterns of adherence and its predictors among older adults on angiotensin-converting enzyme inhibitors (ACEIs)\/angiotensin receptor blockers (ARBs)","volume":"14","author":"Paranjpe","year":"2020","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.jns.2024.123092_bb0125","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.1230","article-title":"Methods for evaluation of medication adherence and persistence using automated databases","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jns.2024.123092_bb0130","article-title":"An assessment of Parkinson\u2019s disease medication treatment patterns in the Medicaid population","volume":"5","author":"Johnsrud","year":"2021","journal-title":"Clin. Park. Relat. Disord."},{"key":"10.1016\/j.jns.2024.123092_bb0135","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1177\/10600280231155489","article-title":"Trajectories of oral anticoagulation adherence and associated clinical outcomes during long-term anticoagulation among medicare beneficiaries with venous thromboembolism","volume":"57","author":"Park","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jns.2024.123092_bb0140","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2024.123092_bb0145","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mdc3.12921","article-title":"Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide","volume":"7","author":"Schade","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.jns.2024.123092_bb0150","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/pds.4917","article-title":"Opening the black box of the group-based trajectory modeling process to analyze medication adherence patterns: an example using real-world statin adherence data","volume":"29","author":"Hickson","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jns.2024.123092_bb0155","doi-asserted-by":"crossref","DOI":"10.1186\/s12877-019-1058-6","article-title":"Patterns of antihypertensive and statin adherence prior to dementia: findings from the adult changes in thought study","volume":"19","author":"Marcum","year":"2019","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.jns.2024.123092_bb0160","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/0049124111400041","article-title":"Group-based trajectory modeling extended to account for nonrandom participant attrition","volume":"40","author":"Haviland","year":"2011","journal-title":"Sociol. Methods Res."},{"key":"10.1016\/j.jns.2024.123092_bb0165","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/aje\/kwac115","article-title":"A framework for descriptive epidemiology","volume":"191","author":"Lesko","year":"2022","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.jns.2024.123092_bb0170","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41416-020-1019-z","article-title":"Let the question determine the methods: descriptive epidemiology done right","volume":"123","author":"Conroy","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jns.2024.123092_bb0175","series-title":"An Introduction to the Bootstrap","author":"Efron","year":"1994"},{"key":"10.1016\/j.jns.2024.123092_bb0180","author":"Jones"},{"key":"10.1016\/j.jns.2024.123092_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120479","article-title":"Safety and effectiveness of istradefylline as add-on therapy to levodopa in patients with Parkinson\u2019s disease: final report of a post-marketing surveillance study in Japan","volume":"443","author":"Takahashi","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2024.123092_bb0190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjopharm.2011.02.004","article-title":"A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity","volume":"9","author":"Gellad","year":"2011","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"10.1016\/j.jns.2024.123092_bb0195","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/mds.22112","article-title":"Adherence to antiparkinson medication in a multicenter European study","volume":"24","author":"Grosset","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2024.123092_bb0200","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/j.1525-1497.2006.00591.x","article-title":"Factors associated with medication refill adherence in cardiovascular-related diseases","volume":"21","author":"Gazmararian","year":"2006","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.jns.2024.123092_bb0205","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/0002512-200926020-00006","article-title":"Challenges of treatment adherence in older patients with Parkinson\u2019s disease","volume":"26","author":"Bainbridge","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jns.2024.123092_bb0210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40263-014-0220-0","article-title":"Medication adherence in patients with Parkinson\u2019s disease","volume":"29","author":"Malek","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jns.2024.123092_bb0215","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1468-1331.2010.03320.x","article-title":"On behalf of the members of the ADHESON study group, socio-demographic and clinical factors influencing the adherence to treatment in Parkinson\u2019s disease: the ADHESON study","volume":"18","author":"Valldeoriola","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2024.123092_bb0220","unstructured":"Cabinet Office, Government of Japan, Annual Report on the Aging Society 2017, (2017). https:\/\/www8.cao.go.jp\/kourei\/whitepaper\/w-2017\/html\/zenbun\/s1_2_1.html (accessed January 15, 2024)."},{"key":"10.1016\/j.jns.2024.123092_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269969","article-title":"Real-world evidence on levodopa dose escalation in patients with Parkinson\u2019s disease treated with istradefylline","volume":"18","author":"Hattori","year":"2023","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jns.2024.123092_bb0230","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/mds.25364","article-title":"Stalevo reduction in dyskinesia evaluation in Parkinson\u2019s disease (STRIDE-PD) investigators, factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson\u2019s disease","volume":"28","author":"Warren Olanow","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2024.123092_bb0235","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2024.123092_bb0240","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/mds.22999","article-title":"Prevalence and cost of medication nonadherence in Parkinson\u2019s disease: evidence from administrative claims data","volume":"25","author":"Davis","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2024.123092_bb0245","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jval.2013.12.003","article-title":"Antiparkinson drug adherence and its association with health care utilization and economic outcomes in a medicare part D population","volume":"17","author":"Wei","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.jns.2024.123092_bb0250","article-title":"Dopamine agonist monotherapy utilization in patients with Parkinson\u2019s disease","volume":"8","author":"Frazer","year":"2023","journal-title":"Clin. Park. Relat. Disord."},{"key":"10.1016\/j.jns.2024.123092_bb0255","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2021.09.1370","article-title":"Longitudinal Oral anticoagulant adherence trajectories in patients with atrial fibrillation","volume":"78","author":"Salmasi","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jns.2024.123092_bb0260","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s11606-016-3747-6","article-title":"Trajectories of diabetes medication adherence and hospitalization risk: a retrospective cohort study in a large state medicaid program","volume":"31","author":"Lo-Ciganic","year":"2016","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.jns.2024.123092_bb0265","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/11538970-000000000-00000","article-title":"The association between adherence to levodopa\/carbidopa\/entacapone therapy and healthcare utilization and costs among patients with parkinson\u02bcs disease","volume":"25","author":"Delea","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jns.2024.123092_bb0270","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.jacc.2021.10.016","article-title":"Can we anticipate nonadherence to anticoagulation?: elegant modeling, but no clear predictions","volume":"78","author":"Skanes","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jns.2024.123092_bb0275","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0022-3999(99)00057-4","article-title":"Patients\u2019 beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness","volume":"47","author":"Horne","year":"1999","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.jns.2024.123092_bb0280","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1146\/annurev-statistics-042522-103837","article-title":"A review of generalizability and transportability","volume":"10","author":"Degtiar","year":"2023","journal-title":"Annu. Rev. Stat. Appl."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24002272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24002272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T19:07:25Z","timestamp":1728241645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24002272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":56,"alternative-id":["S0022510X24002272"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123092","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence to istradefylline in patients with Parkinson's disease: A group-based trajectory analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123092"}}